Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update [Yahoo! Finance]
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 [Yahoo! Finance]